Veristat Supports Antibe Therapeutics for Pain and Inflammation Study
Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B...
Veristat Partners with TRI For Risk-Based Monitoring Technology
Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients
Veristat Strengthens Clinical Operations Capabilities - Acquires Topstone Research
Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma
Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™
Continues Collaboration to Provide Regulatory Submission Support for Additional Patisiran Submissions
SOUTHBOROUGH, MA – August 20, 2018...
Veristat Congratulates Agios on the FDA Approval of TIBSOVO®
The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
SOUTHBOROUGH, MA –...
Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies...
Veristat’s Continued Innovation of Its Clinical Development Strategies and Services Allow the Company to Execute High Quality Trials That...
Veristat Recognized for a Third Consecutive Year on the Inc. 5000 List of America’s...
Veristat’s Growth Positively Impacts Our Ability to Help Clients Achieve Regulatory Approval of their Life-Changing and Life-Saving Therapies
Veristat and AOBiome Establish a Preferred Partnership To Support Ongoing & Impending...
SOUTHBOROUGH, MA – June 19, 2017 – Veristat, a full service Clinical Research Organization (CRO), announced today that Veristat and AOBiome, ...